| Model Number |
KD-655Q |
| Medical Device Problem Code |
Adverse Event Without Identified Device or Use Problem (2993)
|
| Health Effect - Clinical Codes |
Hemorrhage/Blood Loss/Bleeding (1888); Perforation (2001)
|
| Date of Event |
08/23/2022
|
|
Type of Reportable Event
|
Serious Injury
|
|
Additional Manufacturer Narrative
|
|
Since the literature described "dual-knife", we selected "kd-655q" as a representative product.The product was unknown but a representative product was chosen for processing purposes.The suspect device has not been returned to olympus for evaluation.The investigation is in process.The literature article is attached for additional information.Once the investigation has been completed, a supplemental report will be submitted with device evaluation results.
|
| |
|
Event or Problem Description
|
|
Olympus reviewed the following literature titled, "modified cap-assisted endoscopic mucosal resection versus endoscopic submucosal dissection for the treatment of rectal neuroendocrine tumors #10 mm: a randomized noninferiority tria." introduction: although recent guidelines recommend endoscopic resection of rectal neuroendocrine tumors (net) =10 mm, there is no consensus on which endoscopic modality should be performed.We aimed to compare the safety and efficacy of modified cap-assisted endoscopic mucosal resection (memr-c) and endoscopic submucosal dissection (esd) methods for the treatment of rectal net =10 mm.Methods: a randomized noninferiority trial comparing memr-c and esd was conducted.The primary outcome was the histological complete resection rate; the secondary outcomes included en bloc resection rate, operation time, complications, and so on.Subgroup analyses and follow-up were also performed.Results: ninety patients were enrolled, and 79 patients with pathologically confirmed rectal net were finally analyzed, including 38 cases of memr-c and 41 cases of esd.Histological complete resection rate was 97.4% in the memr-c group and 92.7% in the esd group.The noninferiority of memr-c compared with that of esd was confirmed because the absolute difference was 4.7% (2-sided 90% confidence interval, -3.3% to 12.2%; p = 0.616).En bloc resection and successful removal of rectal net were achieved in all patients.Advantages of memr-c over esd included shorter operation time (8.89 ± 4.58 vs 24.8 ± 9.14 minutes, p < 0.05) and lower hospitalization cost ((b)(6), p < 0.05).Postoperative complications were recorded in 4 patients who received memr-c and 2 patients in the esd group (11.5% vs 4.9%, p = 0.509), which were all well managed using endoscopy.Similar findings were observed when subgroup analysis was performed.Type of adverse events/number of patient: bleeding (n = 5), perofration (n = 1).This literature article requires 2 reports.The related patient identifiers are as follows: (b)(6) for mh-593 and (b)(6) for kd-655q.This medwatch report is for patient identifier (b)(6).There is no report of any olympus device malfunction in any procedure described in this study.
|
| |
|
Additional Manufacturer Narrative
|
|
This supplemental report is being submitted to provide a correction to h6 code (type of investigation).Code 4112 added that was inadvertently not included on the previous submission.
|
| |
|
Event or Problem Description
|
|
The following additional information was received: the was no malfunction, nor adverse event that occurred during use of an olympus device in any of the procedures described in the article.
|
| |
|
Additional Manufacturer Narrative
|
|
This report is being supplemented to provide additional information based on the legal manufacturer's final investigation.The device history record was unable to be reviewed for this device since the serial and/or lot number was not provided.However, olympus only releases products to market that meet all manufacturing specifications and final product release criteria.Based on the results of the investigation, the relationship between the device and the adverse event cannot be confirmed.There was no complaint reported on the subject device.There is no evidence of an olympus device malfunction.Therefore, the root cause cannot be determined.This supplemental report includes additional information added to b5.Also, a correction has been made to g2 to include information that was inadvertently not included on the initial medwatch.Olympus will continue to monitor field performance for this device.
|
| |
|
Search Alerts/Recalls
|